RESPONSE UNDER 37 C.F.R. §1.116 EXPEDITED PROCEDURE EXAMINING GROUP 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Beka SOLOMON

Application No.: 09/441,140 Filed: November 16, 1999 Conf. No. 3910

Art Unit: 1642

RZCEIVED CENTRAL FAX CENTER

Examiner, S. Ungar

Washington, D.C. AUG

Date: August 9, 2004

Atty.'s Docket: SOLOMON=14

AUG 0 9 2004

THE COMMISSIONER OF PATENTS 2011 South Clark Place, Mail Stop Crystal Plaza Two, Lobby, Room 1803 Arlington, VA 22202

VIA TELEFACSIMILE

OR

OR

Sir

Transmitted herewith is a [X] Amendment [X0Exhibits A. B. C. D.

in the above-identified application.

- [] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.
- (XX) No additional fee is required.
- [] The fee has been calculated as shown below:

For PREVENTION OF PROTEIN AGGREGATION

	(Col. 1)	(Cal. 2) (Cal. 3)						
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS				
TOTAL.	22	MINUS	•• 89	0				
INDEP.	4	MINUS	26	0				
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM								

	RATE	ADDITIONAL FEE
	x _9	ŝ
	x 43	\$
_]	→ 145	\$
ADDITIO	VAL FEE TOTAL	5

SMALL ENTITY

OTHER THAN SMALL ENTITY									
	RATE	ADDITIONAL FEE							
×	18	\$							
×	86	\$							
+	290	\$							
	TOTAL	\$							

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- "If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" In this space.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" In this space.

The "Highest Number Previously Paid For" (total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.138(e). The appropriate fee required by 37 CFR 1.17 is calculated as shown below;

	Small	Emity									O	ther	Than Small	Ent	ity		
	Respo	nse Filed V	Vith	in							R	espo	nse Filed V	/ith)	n		
	[]	First	-	\$ 55.00							Į	1	First	_	\$	110.00	
	{]	Second	-	\$ 210.00							i	3	Second	_	\$	420.00	
	()	Third	-	\$ 475.00							í	ĭ	Third	-	\$	\$50.00	
	[]	Fourth	_	\$ 740.00							ľ	1	Fourth	_	\$	1480.00	
	Month After Time Period Set				Month After Time Period Set												
}) alrea							_	_					
)	Credit (Card Payme	ent l	Form, PTO-2	20\$8, is a	altaci	hed, sut	thorizing	paymer	it in the	an	กอบกุล	of \$.				
1	A chec	k in the amo	uni	t of \$		_ is :	alteche	d (check	no.).								

The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneya for Applicant(s)

Roger L. Browdy Registration No. 25,618

Facsimile: (202) 737-3528 Telephone: (202) 626-5197

[]

RESPONSE UNDER 37 C.F.R. \$1.116 EXPEDITED PROCEDURE EXAMINING GROUP 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED CENTRAL FAX CENTER

Atty. Docket: SOLOMON=1R

AUG 0 9 2004

In re Application of:

Conf. No.: 3910

(()

Beka SOLOMON

Art Unit: 1647

Examiner: C. Nichols

Appln. No.: 09/441,140

Filed: November 16, 1999

Washington, D.C.

For: PREVENTION OF PROTEIN

) August 9, 2004

AGGREGATION

AMENDMENT

U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Mail Stop Amendment Non-Fee Crystal Plaza Two, Lobby, Room 1803 Arlington, Virginia 22202

sir:

In response to the Office Action of June 10, 2004, please amend as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at column 11, line 20, with the following:

Amyloid peptides, A β 1-40 (Cat. No. A-5813) and A β 1-28 (Cat. No. [A-1084] <u>A-0184</u>) corresponding to amino acids 1-40 and 1-28 of A β respectively, were purchased from Sigma Chemical Co., St. Louis, Mo., USA).

IN THE CLAIMS

1. A method of selecting an anti-aggregation molecule having the chaperone-like activity of anti-aggregation, wherein the anti-aggregation molecule is selected from the group consisting of a monoclonal antibody, a